Identifies themes and clusters of stock movements
Market TodayThemes and Stocks SummaryThematic Stock SearchClick here for daily refresh schedule
CRIS - Curis Inc
$12.60
-0.20(-1.56%)3:43:42 PM 1/19/2021
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation; and Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors. The company's products in pipeline include CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and DarwinHealth, Inc. to characterize biomarkers and tumor subtype alignments to identify therapeutic opportunities. The company was founded in 2000 and is headquartered in Lexington, Massachusetts.
Stock Chart

Summary:

  • Although price ZSCore is at a high level but it has returned from prior high level and momentum has slowed down.
  • Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
  • RSI is at a high level of 85. A high level of RSI indicates the stock is overbought.
  • MACD is crossing MACD signal line at 0.2. MACD crossing signal line is bullish signal.

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
leak data

Related Topics

Peers

Stock news

    01/14/2021CRIS
    Curis to Present at B. Riley Securities Virtual Oncology Investor Conference

    Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference on Thursday, January 21, 2021 at 11:00 am ET.

    01/8/2021CRIS
    Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on January 4, 2021, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 185,000 shares of Curis common stock to three new employees, with a grant date of January 4, 2021 (the "Q1 2021 Inducement Grants").

    01/5/2021CRIS
    Curis to Present at H.C. Wainwright & Co. Bioconnect 2021 Virtual Conference

    Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present at the H.C. Wainwright & Co. Bioconnect 2021 Virtual Conference. The presentation will be available for on-demand viewing starting on Monday, January 11, 2021 at 6:00 am ET.

    12/22/2020CRIS
    CytomX Therapeutics Appoints Dr. Mani Mohindru to Board of Directors

    SOUTH SAN FRANCISCO, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today announced the appointment of Mani Mohindru, PhD to the Company’s board of directors. Dr. Mohindru brings to CytomX deep and varied experience across the life sciences industry, with particular experience in finance and c...

    12/14/2020CRIS
    Curis Announces Closing of Public Offering of Common Stock with $169.6 Million in Gross Proceeds, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

    Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the closing of its underwritten public offering of 29,500,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase up to an additional 3,847,826 shares, at the public offering price of $5.75 per share (the Offering). Curis expects the net proceeds from the Offering to be approximately $159.1 mi...

    12/11/2020CRIS
    Curis (CRIS) Surges: Stock Moves 5% Higher

    Curis (CRIS) saw a big move last session, as its shares jumped 5% on the day, amid huge volumes.

    12/11/2020CRIS
    Is CRIS A Good Stock To Buy Now?

    The 800+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the third quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]

    12/9/2020CRIS
    Curis (CRIS) Stock Is up 420% in Two Days. How Much Higher Can It Go?

    Investors love biotech stocks for the lottery ticket-like returns they can offer if a company strikes medical gold. Case in point: Curis Inc (CRIS) shares skyrocketed by an extraordinary 420%, in just two days, after the cancer drug maker reported encouraging data from its early-stage trial in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS).Specifically, in the Phase 1 trial evaluating monotherapy CA-4948, the orally administered protein kinase inhibitor’s...

    12/9/2020CRIS
    Curis Announces Pricing of Public Offering of Common Stock

    Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the pricing of an underwritten public offering of 25,652,174 shares of its common stock at a public offering price of $5.75 per share for total gross proceeds of approximately $147.5 million (the "Offering"). Curis has granted the underwriters a 30-day option to purchase up to an additional 3,847,826 shares of common stock on the same terms and con...